The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis - PubMed (original) (raw)
The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis
R Hubbard et al. Rheumatology (Oxford). 2002 Jun.
Abstract
Objectives: Previous reports have suggested that patients who have fibrosing alveolitis in association with a connective tissue disease (FA-CTD) have a better prognosis than patients with 'lone' cryptogenic fibrosing alveolitis (LCFA). The present study was designed to compare the survival of a general population-based sample of patients with FA-CTD and LCFA both with each other and with the general population.
Methods: A survival analysis was performed using data for 107 patients with FA-CTD, 872 with LCFA and 5958 controls matched for age, sex and general practice, drawn from the General Practice Research Database. The data were analysed using Cox regression, adjusting for a number of potential confounders, including age, gender, smoking habit and use of oral corticosteroids.
Results: The median follow-up period was 2.1 yr and during this time 54 (50%) patients with FA-CFA, 386 (44%) patients with LCFA and 601 (10%) controls died. The mortality rates for patients with FA-CTD, LCFA and the controls were 284, 270 and 41 per 1000 person-yr respectively. After adjusting for age, gender, smoking habit and exposure to oral corticosteroids, patients with FA-CTD had a marginally worse survival than patients with LCFA (hazard ratio 1.20, 95% confidence interval 0.90-1.61). Compared with the general population controls, patients with either LCFA or FA-CTD had a considerably worse prognosis (hazard ratio 5.56, 95% confidence interval 4.77-6.49).
Conclusions: The median survival in patients with fibrosing alveolitis is less then 3 yr. We found no evidence to support previous reports of a better prognosis amongst patients with FA-CTD.
Comment in
- Survival in fibrosing alveolitis associated with rheumatoid arthritis is better than cryptogenic fibrosing alveolitis.
Saravanan V, Kelly CA. Saravanan V, et al. Rheumatology (Oxford). 2003 Apr;42(4):603-4; author reply 604-5. doi: 10.1093/rheumatology/keg139. Rheumatology (Oxford). 2003. PMID: 12649414 No abstract available.
Similar articles
- Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.
Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, Newman-Taylor AJ, Du Bois RM. Wells AU, et al. Am J Respir Crit Care Med. 1994 Jun;149(6):1583-90. doi: 10.1164/ajrccm.149.6.8004317. Am J Respir Crit Care Med. 1994. PMID: 8004317 - Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study.
Adzić TN, Pesut DP, Nagorni-Obradović LM, Stojsić JM, Vasiljević MD, Bouros D. Adzić TN, et al. Respir Med. 2008 Apr;102(4):620-4. doi: 10.1016/j.rmed.2007.10.022. Epub 2008 Jan 4. Respir Med. 2008. PMID: 18178071 - Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis?
Navaratnam V, Ali N, Smith CJ, McKeever T, Fogarty A, Hubbard RB. Navaratnam V, et al. Respir Med. 2011 Dec;105(12):1925-30. doi: 10.1016/j.rmed.2011.08.015. Epub 2011 Sep 15. Respir Med. 2011. PMID: 21924888 - [Undifferentiated connective tissue disease].
Bodolay E, Szegedi G. Bodolay E, et al. Orv Hetil. 2009 May 10;150(19):867-72. doi: 10.1556/OH.2009.28610. Orv Hetil. 2009. PMID: 19403430 Review. Hungarian. - Pulmonary arterial hypertension complicating connective tissue diseases.
Hassoun PM. Hassoun PM. Semin Respir Crit Care Med. 2009 Aug;30(4):429-39. doi: 10.1055/s-0029-1233312. Epub 2009 Jul 24. Semin Respir Crit Care Med. 2009. PMID: 19634082 Review.
Cited by
- Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis.
Munson JC, Kreider M, Chen Z, Christie JD, Kimmel SE. Munson JC, et al. Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):756-62. doi: 10.1002/pds.1959. Pharmacoepidemiol Drug Saf. 2010. PMID: 20582912 Free PMC article. - Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.
Gabriel SE, Michaud K. Gabriel SE, et al. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669. Epub 2009 May 19. Arthritis Res Ther. 2009. PMID: 19519924 Free PMC article. Review. - Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study.
Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O Callaghan A, Solans-Laqué R, Palliza E, Muñoz X, Vilardell-Tarrés M. Simeón-Aznar CP, et al. Open Respir Med J. 2008;2:39-45. doi: 10.2174/1874306400802010039. Epub 2008 May 15. Open Respir Med J. 2008. PMID: 19340324 Free PMC article. - Rheumatoid lung disease.
Brown KK. Brown KK. Proc Am Thorac Soc. 2007 Aug 15;4(5):443-8. doi: 10.1513/pats.200703-045MS. Proc Am Thorac Soc. 2007. PMID: 17684286 Free PMC article. - Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.
Mori S. Mori S. Clin Med Insights Circ Respir Pulm Med. 2015 Sep 8;9(Suppl 1):41-9. doi: 10.4137/CCRPM.S23288. eCollection 2015. Clin Med Insights Circ Respir Pulm Med. 2015. PMID: 26401101 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical